Biogen (NASDAQ:BIIB) Given New $200.00 Price Target at Sanford C. Bernstein

Biogen (NASDAQ:BIIB) had its price target dropped by equities researchers at Sanford C. Bernstein from $201.00 to $200.00 in a report released on Thursday,MarketScreener reports. Sanford C. Bernstein’s target price points to a potential upside of 5.27% from the stock’s previous close.

Several other equities analysts have also recently commented on BIIB. Oppenheimer upped their price target on Biogen from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday, April 1st. Mizuho upped their price target on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Rothschild & Co Redburn upped their price objective on Biogen from $150.00 to $180.00 and gave the company a “neutral” rating in a research note on Wednesday, April 22nd. Piper Sandler upgraded Biogen from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $177.00 to $214.00 in a research report on Tuesday, April 14th. Finally, Wolfe Research set a $231.00 price target on Biogen in a research report on Monday, February 9th. Fourteen equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $213.85.

Biogen Stock Up 0.4%

Shares of NASDAQ:BIIB traded up $0.71 on Thursday, reaching $189.99. The company had a trading volume of 65,672 shares, compared to its average volume of 1,317,165. Biogen has a twelve month low of $115.25 and a twelve month high of $202.41. The company has a quick ratio of 2.03, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $27.88 billion, a P/E ratio of 20.39, a P/E/G ratio of 1.63 and a beta of 0.16. The stock has a 50-day moving average price of $184.52 and a 200 day moving average price of $176.06.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the company earned $3.02 EPS. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities analysts expect that Biogen will post 14.91 EPS for the current year.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.18% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Reflection Asset Management bought a new position in shares of Biogen in the 4th quarter worth $25,000. WPG Advisers LLC raised its stake in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after buying an additional 117 shares during the period. Accredited Wealth Management LLC raised its stake in Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 185 shares during the period. First Horizon Corp acquired a new stake in Biogen during the 4th quarter worth $30,000. Finally, WFA of San Diego LLC acquired a new stake in Biogen during the 2nd quarter worth $32,000. 87.93% of the stock is currently owned by institutional investors.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.